Tectonic Therapeutic (TECX) Preferred Stock Liabilities (2017 - 2023)
Tectonic Therapeutic's (TECX) quarterly Preferred Stock Liabilities came in at $80.6 million in Q4 2023, up 204.25% on a QoQ basis from $26.5 million in Q4 2017.
Tectonic Therapeutic (TECX) Preferred Stock Liabilities (2017 - 2023) Analysis & Trends
Tectonic Therapeutic (TECX) has 2 years of Preferred Stock Liabilities data on file, last reported at $80.6 million in Q4 2023.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $80.6 million in Q4 2023; TTM through Dec 2023 was $80.6 million, a N/A change from a year earlier, with the FY2023 full-year figure at $80.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2023 stood at $80.6 million, up from $26.5 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for TECX reached as high as $80.6 million in Q4 2023 and fell as low as $80.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Tectonic Therapeutic | 595.23 Mn | 595.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 80.63 Mn |
| Dec 31, 2017 | 26.50 Mn |